Business Context and Reporting Period
Genprex, Inc. (GNPX), a Delaware corporation and emerging growth company, filed this Form 8-K on December 29, 2022. The report details the entry into a material definitive agreement with the University of Pittsburgh (UP) regarding gene therapy technology for Type 2 diabetes.
Key Financial Metrics
This filing is a Current Report and does not contain audited financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data provided relates to the terms of the new license agreement:
- Aggregate Milestone Payments: Up to approximately $4,000,000.
- License Fees: Includes an initial license fee, annual maintenance fees, and patent prosecution expenses.
- Royalties: Running single-digit royalties and minimum annual royalties in a fixed cash amount.
- Sublicensing Share: Low double-digit percentage share of non-royalty sublicense income.
Material Changes
The primary material change is the execution of the Exclusive License Agreement with UP on December 29, 2022. This agreement grants Genprex:
- A worldwide, exclusive license to patent rights and related technology for gene therapy using Pdx1 and MafA transcription factors.
- A worldwide, non-exclusive license to use related know-how.
- The right to sublicense the technology subject to UP's prior written approval.
Outlook, Risks, and Management Commentary
Management Obligations: Genprex must use diligent and commercially reasonable efforts to bring the technology to market, achieve specified milestones within set timeframes, and submit annual progress reports (and quarterly reports post-commercial sale).
Term and Termination: The agreement lasts until the later of 20 years after the first commercial sale or the expiration of the last valid patent claim. UP may terminate for uncured default, failure to meet milestones, or bankruptcy. Genprex may terminate with six months' notice upon payment of accrued amounts.
Risks and Contingencies: The agreement is subject to U.S. government rights, which may hold a nonexclusive, paid-up license to practice the inventions. UP retains a royalty-free, nonexclusive right for non-commercial education and research.
Investor Verification Checklist
- Verify the specific amounts for the initial license fee and annual maintenance fees, as the filing only states these are payable without listing exact figures.
- Review the specific milestones and time periods required to avoid termination by UP.
- Examine the full text of the Exclusive License Agreement (Exhibit 10.1) for redacted confidential terms.
- Monitor the press releases dated January 4 and 5, 2023 (Exhibits 99.1 and 99.2) for additional context on the partnership.